Results of a Spanish Lung Cancer Group Phase III Trial

James Metz, MD

University of Pennsylvania Cancer
Last Modified: May 12, 2001

Share article


Presenter: V. Alberola
Affiliation: Spanish Lung Cancer Group

Background:

    The Spanish Lung Cancer Group has found in previous studies that a combination of Gemcytabine/Cisplatin is an effective regimen for the treatment of advanced lung cancer. This study was designed to evaluate this regimen against two other chemotherapy regimens, including a regimen without Cisplatin based therapy.

Materials and Methods:

  • This study included patients with stage IIIb and IV NSCLC.
  • Most patients were has ECOG performance status 0 or 1.
  • Patients were randomized to receive CG (n=166) vs CGV (n=176) vs GV/IV (n=175)

Results:

  • anemia and nausea/vomiting were significantly increased in the CGV regimen
  • The median survival, 1 year survival, and time to progression were not significantly different between the arms

Authors' Conclusions

  • The response rate, time to progression, and survival were the same for CG as the addition of a 3rd agent
  • The hematologic toxicity was increased in the Cisplatin containing arms
  • There was no survival differences between the regimens

Clinical/Scientific Implications:

  • The addition of a third agent to a Cisplatin containing regimen was not shown to increase the benefits for patients
  • The experimental arms in this study were not superior to the control are of CG

ASCO Abstract 1229

Saturday | Sunday | Monday | Tuesday

OncoLink ASCO 2001 coverage is provided by an unrestricted educational grant from Amgen



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More